Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Hybrigenics Pharma
Bone Gets Lucky Break At Last With Medsenic Merger
Faced with a scarily short cash runway and an ongoing expensive mid-stage study of an allogeneic cell therapy for the treatment of delayed-union bone fractures, Bone Therapeutics has found a saviour in France's Medsenic.
Deal Watch: Novo Nordisk Links With Flagship To Create Cardiometabolic, Rare Disease Portfolio
The Danish diabetes titan teams with Moderna’s founder on cardiometabolic R&D. Troubled cell therapy biotech Bone Therapeutics negotiates reverse merger with Medsenic.
Bone Therapeutics More Interested In A Partner Than A Buyer
Miguel Forte, Bone Therapeutics CEO, has told Scrip that another approach from French company Hybrigenics about a merger came as a surprise, adding that his priority is the expansion of the Belgian biotech's allogenic cell therapy platform after the recent failure of its Phase III asset for knee osteoarthritis pain.
Pipeline Watch: Xarelto, CVT-301 And Ameluz Phase III Readouts
Pipeline Watch has been updated to bring greater depth and detail to a potential therapeutic product’s progress through the R&D pipeline. The table brings you a snapshot of selected late-stage clinical trial events in the pharma and biotech industries.
- Large Molecule
Drug Discovery Tools
- Other Names / Subsidiaries
- Hybrigenics SA
- Hybrigenics Pharma Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.